Preliminary, Open-Label, Pilot Study of Add-On Oral Δ9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder

@article{Roitman2014PreliminaryOP,
  title={Preliminary, Open-Label, Pilot Study of Add-On Oral $\Delta$9-Tetrahydrocannabinol in Chronic Post-Traumatic Stress Disorder},
  author={Pablo D. Roitman and Raphael Mechoulam and Rena Cooper-Kazaz and Arieh Y. Shalev},
  journal={Clinical Drug Investigation},
  year={2014},
  volume={34},
  pages={587-591}
}
Background and ObjectivesMany patients with post-traumatic stress disorder (PTSD) achieve but partial remission with current treatments. [] Key Method This open-label study evaluates the tolerance and safety of orally absorbable Δ9-tetrahydrocannabinol (THC) for chronic PTSD.MethodsTen outpatients with chronic PTSD, on stable medication, received 5 mg of Δ9-THC twice a day as add-on treatment.ResultsThere were mild adverse effects in three patients, none of which led to treatment discontinuation.

Use of cannabinoids for the treatment of patients with post-traumatic stress disorder

Cannabinoids have been shown to be an effective treatment option for patients with PTSD, Besides aiding to relieve the symptoms and enhance extinction training, they also are relatively well tolerated.

The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial

All treatment groups, including placebo, showed good tolerability and significant improvements in PTSD symptoms during three weeks of treatment, but no active treatment statistically outperformed placebo in this brief, preliminary trial.

The Efficacy of Psychedelic-Assisted Therapy in Managing Post-traumatic Stress Disorder (PTSD): A New Frontier?

Post-traumatic stress disorder (PTSD) is a significant public health concern for which existing therapies are only marginally effective. Indisputably, the primary line of treatment for PTSD is

Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention

The end result of the current clinical and preclinical data is that cannabinoid agents may offer therapeutic benefits for PTSD, and there is a need for large-scale clinical trials examining the potential decrease in PTSD symptoms with the use of cannabis.

The Effectiveness of Cannabinoids in the Treatment of Posttraumatic Stress Disorder (PTSD): A Systematic Review

It is found that cannabinoids may decrease PTSD symptomology, in particular sleep disturbances and nightmares, and indicates that future well-controlled, randomized, double-blind clinical trials are highly warranted.

Marijuana and other cannabinoids as a treatment for posttraumatic stress disorder: A literature review

Although controlled research on marijuana and other cannabinoids’ effects on PTSD remains limited, rapid shifts in the legal landscape may now enable such studies, potentially opening new avenues in PTSD treatment research.

Endocannabinoid System as Therapeutic Target of PTSD: A Systematic Review

Evidence about the efficacy and safety of medicinal cannabidiol (CBD), Δ9-tetrahydrocannabinol (Δ9-THC), and nabilone in PTSD treatment is summarized.

Trauma and Addiction—How to Treat Co-occurring PTSD and Substance Use Disorders

The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder.

Evidence is provided that the types of cannabis available in recreational and medical cannabis dispensaries might hold promise as an alternative treatment for PTSD and how different preparations of cannabis impact PTSD and functioning is investigated.
...

References

SHOWING 1-10 OF 30 REFERENCES

The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD)

  • G. Fraser
  • Psychology, Medicine
    CNS neuroscience & therapeutics
  • 2009
The results of this study indicate the potential benefits of nabilone, a synthetic cannabinoid, in patients with PTSD experiencing poor control of nightmares with standard pharmacotherapy.

Open-Label, Add-on Study of Tetrahydrocannabinol for Chronic Nonmalignant Pain

It is concluded that oral THC may be a valuable therapeutic option for selected patients with CNMP that are unresponsive to previous treatments, though further research is warranted to characterize those patients.

Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence.

It is shown that recent studies provided supporting evidence that PTSD patients may be able to cope with their symptoms by using cannabis products and it is concluded that further studies are warranted in order to evaluate the therapeutic potential of cannabinoids in PTSD.

PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program

Cannabis is associated with reductions in PTSD symptoms in some patients, and prospective, placebo-controlled study is needed to determine efficacy of cannabis and its constituents in treating PTSD.

Effects of Smoked Cannabis and Oral δ9-Tetrahydrocannabinol on Nausea and Emesis After Cancer Chemotherapy

A review of previously unpublished state-run clinical trials with Cannabis sativa (marijuana and/ or δ9-tetrahydrocannabinol capsules) to test efficacy in reducing nausea and vomiting following cancer chemotherapy is warranted.

Cannabis use among military veterans after residential treatment for posttraumatic stress disorder.

Results demonstrated that lower levels of change in PCL-M scores between treatment intake and discharge were significantly predictive of greater frequency of cannabis use at 4-month follow-up (p < .05), even after accounting for the effects of length of treatment stay and frequency of Cannabis use during the 2 months before treatment intake.

Dronabinol and Marijuana in HIV-Positive Marijuana Smokers: Caloric Intake, Mood, and Sleep

For HIV-positive marijuana smokers, both dronabinol (at doses 8 times current recommendations) and marijuana were well tolerated and produced substantial and comparable increases in food intake.

Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse.

Findings suggest that symptoms of PTSD begin soon after exposure to trauma, that hyperarousal symptoms are the first symptoms to occur, that the natural course of alcohol and substance abuse parallels that of PTSD, and that specific substances have specific effects on PTSD symptoms.

Elevated Brain Cannabinoid CB1 Receptor Availability in Posttraumatic Stress Disorder: A Positron Emission Tomography Study

It is suggested that abnormal CB1 receptor-mediated anandamide signaling is implicated in the etiology of PTSD, and provide a promising neurobiological model to develop novel, evidence-based pharmacotherapies for this disorder.

Effect of Sublingual Application of Cannabinoids on Intraocular Pressure: A Pilot Study

A single 5 mg sublingual dose of Δ-9-THC reduced the IOP temporarily and was well tolerated by most patients, while the higher dose of CBD produced a transient elevation of IOP at 4 hours after administration.